Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones

Journal of Clinical Investigation

Volumn 112, Issue 4, 2003, Pages 608-618

  Norris, Andrew W ^a,b   Chen, Lihong ^a   Fisher, Simon J ^a   Szanto, Ildiko ^a   Ristow, Michael ^a   Jozsi, Alison C ^a   Hirshman, Michael F ^a   Rosen, Evan D ^c   Goodyear, Laurie J ^a   Gonzalez, Frank J ^d   Spiegelman, Bruce M ^a   Kahn, C Ronald ^a,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; 2,4 THIAZOLIDINEDIONE; 2,4-THIAZOLIDINEDIONE; CELL RECEPTOR; DEOXYGLUCOSE; FATTY ACID; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; GENE EXPRESSION; GLUCOSE TRANSPORT; HORMONE ACTION; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIPID METABOLISM; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SKELETAL MUSCLE; ADIPOSE TISSUE; ALLELE; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; DBA MOUSE; DNA MICROARRAY; GENETIC RECOMBINATION; GENETICS; GENOTYPE; GLUCOSE TOLERANCE TEST; MALE; METABOLISM; MOUSE MUTANT; MUSCLE; PHYSIOLOGY; TIME; TRANSGENIC MOUSE;

ADIPOSE TISSUE; ALLELES; ANIMALS; DEOXYGLUCOSE; FATTY ACIDS; GENOTYPE; GLUCOSE; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, GENETIC; MUSCLE, SKELETAL; MUSCLES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINATION, GENETIC; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 85047693638     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI17305     Document Type: Article

References (65)

1. Martin, B.C., et al. 1992. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 340:925-929.
2. Lillioja, S., et al. 1993. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N. Engl. J. Med. 329:1988-1992.
3. DeFronzo, R.A., et al. 1981. The effect of insulin on the disposal of intravenous glucose: results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes. 30:1000-1007.
4. Veroni, M.C., Proietto, J., and Larkins, R.G. 1991. Evolution of insulin resistance in New Zealand obese mice. Diabetes. 40:1480-1487.
5. Petersen, K.F., et al. 2000. Mechanism of troglitazone action in type 2 diabetes. Diabetes. 49:827-831.
6. Kraegen, E.W., James, D.E., Jenkins, A.B., Chisholm, D.J., and Storlien, L.H. 1989. A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. Metabolism. 38:1089-1093.
7. Zierath, J.R., et al. 1998. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology. 139:5034-5041.
8. Lehmann, J.M., et al. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:12953-12956.
9. Rosen, E.D., and Spiegelman, B.M. 2001. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276:37731-37734.
10. Rosen, E.D., et al. 2002. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 16:22-26.
11. Vidal-Puig, A.J., et al. 1997. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99:2416-2422.
12. Kruszynska, Y.T., et al. 1998. Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non-insulin-dependent diabetes mellitus. J. Clin. Invest. 101:543-548.
13. Spiegelman, B.M. 1998. PPARTγ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:507-514.
14. Hallakou, S., et al. 1997. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 46:1393-1399.
15. Chao, L., et al. 2000. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106:1221-1228.
16. Burant, C.F., et al. 1997. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100:2900-2908.
17. Arakawa, K., et al. 1998. Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells. Br. J. Pharmacol. 125:429-436.
18. Ciaraldi, T.P., Gilmore, A., Olefsky, J.M., Goldberg, M., and Heidenreich, K.A. 1990. In vitro studies on the action of CS-045, a new anti-diabetic agent. Metabolism. 39:1056-1062.
19. Akiyama, T.E., et al. 2002. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell Biol. 22:2607-2619.
20. Bruning, J.C., et al. 1998. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell. 2:559-569.
21. Cui, Y., et al. 2002. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J. Biol. Chem. 277:17830-17835.
22. Wahl, G.M., Stern, M., and Stark, G.R. 1979. Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl-paper and rapid hybridization by using dextran sulfate. Proc. Natl. Acad. Sci. U. S. A. 76:3683-3687.
23. Lyles, G.A., and Archer, D.R. 1986. Monoamine oxidase activities in dissociated cell fractions from rat skeletal muscle. J. Pharm. Pharmacol. 38:288-293.
24. Fisher, S.J., et al. 1996. Determinants of glucose turnover in the pathophysiology of diabetes: an in vivo analysis in diabetic dogs. Diabetes Metab. 22:111-121.
25. Fisher, S.J., et al. 1996. A moderate decline in specific activity does not lead to an underestimation of hepatic glucose production during a glucose clamp. Metabolism. 45:587-593.
26. Kim, J.K., et al. 2000. Redistribution of substrates to adipose tissue in mice with selective insulin resistance in muscle promotes obesity. J. Clin. Invest. 105:1791-1797.
27. Hayashi, T., Hirshman, M.F., Kurth, E.J., Winder, W.W., and Goodyear, L.J. 1998. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes. 47:1369-1373.
28. Salmon, D.M., and Flatt, J.P. 1988. Effect of dietary fat content on the incidence of obesity among ad libitum fed mice. Int. J. Obes. 9:443-449.
29. Hill, A.L., Phelan, S.A., and Loeken, M.R. 1998. Reduced expression of pax-3 is associated with overexpression of cdc46 in the mouse embryo. Dev. Genes Evol. 208:128-134.
30. Metzger, D., Clifford, J., Chiba, H., and Chambon, P. 1995. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc. Natl. Acad. Sci. U. S. A. 92:6991-6995.
31. Matsusue, K., et al. 2003. Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111:737-747. doi:10.1172/JCI200317223.
32. Zisman, A., et al. 2000. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med. 6:924-928.
33. Dudzinski, K.M., and Neff, N.A. 1990. A technique for the combination of clearing, staining, and injecting small mammals. Stain Technol. 65:113-118.
34. Morgan, J.E. 1988. Myogenicity in vitro and in vivo of mouse muscle cells separated on discontinuous Percoll gradients. J. Neurol. Sci. 85:197-207.
35. Inscho, E.W., Wilfinger, W.W., and Banks, 1986. Dissociation and enrichment of rat arrial myocytes containing atrial natriuretic factor (ANF). Horm. Res. 24:26-37.
36. Wang, J., et al. 1999. Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat. Genet. 21:133-137
37. Lapsys, N.M., et al. 2000. Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor gamma expression in human skeletal muscle. J. Clin. Endocrinol. Metab. 85:4293-4297.
38. Barak, Y., et al. 1999. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4:585-595.
39. Yamauchi, T., et al. 2001. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276:41245-41254.
40. Miles, P.D.G., Barak, Y., He, W., Evans, R.M., and Olefsky, J.M. 2000. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105:287-292.
41. Ristow, M., Muller-Wieland, D., Pfeiffer, A., Krone, W., and Kahn, C.R. 1998. Obesity associated with a mutation in a generic regulator of adipocyte differentiation. N. J. Med. 339:953-959.
42. Barroso, I., et al. 1999. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 402:880-883.
43. Altshuler, D., et al. 2000. The common PPARgamma Pro 12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 2000:76-80.
44. Deeb, S.S., et al. 1998. A Pro 12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20:284-287.
45. Kim, J.K., et al. 2001. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J. Clin. Invest. 108:153-160. doi:10.1172/JCI200110294
46. Cheung, A.T., Wang, J. Ree, D. Kolls, J.K., and Bryer-Ash, M. 2000. Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes. 49:810-819.
47. Berg, A.H., Combs, T.P., Du, X., Brownlee, M., and Scherer, P.E. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7:947-953.
48. Kelley, D.E., and Mandarino, L.J. 2000. Fuel selection in human skeletal muscle in insulin resistance: a reexaminatton. Diabetes. 49:677-683.
49. Ye, J.M., et al. 2001. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity. in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes. 50:411-417.
50. Cha, B.S., et al. 2001. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia. 44:444-452.
51. Way, J.M., et al. 2001. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology. 142:1269-1277.
52. Leone, T.C., Weinheimer, C.J., and Kelly, D.P. 1999. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. U. S. A. 96:7473-7478.
53. Aoyama, T., et al. 1998. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 273:5678-5684.
54. Auboeuf, D., et al. 1997. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46:1319-1327.
55. Muoio, D.M., et al. 2002. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator -activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J. Biol. Chem. 277:26089-26097.
56. Dobbins, R.L., et al. 2001, Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes. 50:123-130.
57. Blaak, E.E., Aggel-Leijssen, D.P., Wagenmakers, A.J., Saris, W.H., and van Baak, M.A. 2000. Impaired oxidation of plasma-derived fatty acids in type 2 diabetic subjects during moderate-intensity exercise. Diabetes. 49:2102-2107.
58. Blaak, E.E., et al. 2000. Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. Am. J. Physiol. Endocrinol. Metab. 279:E146-E154.
59. Steppan, C.M., and Lazar, M.A. 2002. Resistin and obesity-associated insulin resistance. Trends Endocrinol. Metab. 13:18-23.
60. Hevener, A.L., Reichart, D., Janez, A., and Olefsky, J. 2001. Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male Wistar rats. Diabetes. 50:2316-2322.
61. McTernan, P.G., et al. 2002. Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes. 51:1493-1498.
62. Steppan, C.M., et al. 2001. The hormone resistin links obesity to diabetes. Nature. 409:307-312.
63. Maeda, N., et al. 2001. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 50:2094-2099.
64. Okuno, A., et al. 1998. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101:1354-1361.
65. Martin, G., et al. 2000. Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target. J. Biol. Chem. 275:12612-12618.